DroneShield's Backlog Is Growing, But the Chart Keeps Pointing Down

DroneShield's shares fall 9% in 7 days as backlog hits A$206M; H1 results on Aug 26 to test margin recovery and FY26 guidance.

The counter-drone specialist has spent the past week watching its share price slide while its order book swells — a disconnect that leaves investors with a clear focal point: the half-year results due on August 26.

Shares closed Friday at €1.21, down 2.5 percent for the session and marking a fourth consecutive daily decline. The stretch has erased 9.1 percent over seven trading days, leaving the stock roughly 15 percent below its 50-day moving average of €1.43. Technical indicators offer little comfort: the relative strength index sits at 41.3, not yet in oversold territory, while 30-day annualized volatility of 74 percent underscores just how jittery trading has become.

A Product Launch Timed to Geopolitical Demand

The company used August 10 to unveil RfRecon, a portable radio-frequency reconnaissance platform designed to detect, identify, locate and assess electromagnetic activity in tactical settings. Hours after the announcement, management hosted an investor briefing walking through the system's technical specifications and potential deployment scenarios.

The timing looks deliberate. Reuters has reported that South Korea and the United States scheduled extensive military exercises for the second half of August, including training against drones, GPS jamming and cyberattacks. Those maneuvers highlight the growing demand for electronic surveillance and counter-drone technology — precisely the space DroneShield is targeting.

The RfRecon launch follows the earlier introduction of RfAI-3, a new generation of the company's RF-detection engine designed to recognize unknown and evolving drone threats more reliably. Management has framed these product initiatives as a way to strengthen the competitive position even as US rivals press for growth.

The Backlog Tells a Stronger Story

Behind the product push sits a pipeline that has expanded considerably. Committed revenue — the sales already secured by contract — stood at A$206 million as of July 28, up from A$161 million at the end of May. First-half revenue came in at A$125.8 million, a 74 percent improvement over the prior-year period.

Yet the math required to hit the full-year target remains demanding. To reach the guided range of A$250 million to A$270 million in Australian dollars for fiscal 2026, the company needs to secure and execute another A$44 million to A$64 million in orders within a matter of months. Management reaffirmed that guidance at the Canaccord Genuity Growth Conference in August.

The backlog figure also carries a caveat: the company lowered its full-year forecast in July, and investors will be watching whether the August 26 results show that revision was conservative or whether further disappointment lurks.

Margin Recovery Is the Key Question

The half-year numbers, covering the period ended June 30, will also reveal whether the gross margin can bounce back. It slipped to roughly 60 percent in the first half from 65 percent previously. Management expects a return toward 65 percent in the second half, driven by new hardware generations and a rising share of recurring software revenue.

European demand remains a supporting pillar. Late July brought a A$23.2 million order from a European military client, secured through distribution partner COBBS BELUX BV.

Institutional Moves and a Waiting Game

The shareholder register has shifted too. JPMorgan Chase lifted its stake in early August from 5.15 percent to 6.68 percent, crossing the disclosure threshold for significant holdings. Citigroup soon followed with its own filing showing a position above 5 percent. Market observers briefly linked the disclosures to share-price weakness, though such accumulation by major institutions is typically read as a vote of confidence — even if it doesn't translate into immediate price gains.

The stock's market capitalization stands at roughly €1.11 billion, a far cry from the 52-week high of €3.79 reached in early October. For now, the fundamental story — strong half-year growth, a swelling backlog and fresh product launches — remains at odds with a chart that keeps heading south. August 26 will determine which narrative wins out.